Invivyd, Inc. (NASDAQ: IVVD)

Sector: Healthcare Industry: Biotechnology CIK: 0001832038
P/B 3.17
P/E -4.94
P/S 5.91
Market Cap 295.49 Mn
ROIC (Qtr) -87.96
Div Yield % 0.00
Rev 1y % (Qtr) 41.17
Total Debt (Qtr) 2.68 Mn
Debt/Equity (Qtr) 0.03

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 84.97M provide 78.46x coverage of short-term debt 1.08M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 139.16M provides 51.98x coverage of total debt 2.68M, indicating robust asset backing and low credit risk.
  • Tangible assets of 139.16M provide robust 5.50x coverage of other current liabilities 25.31M, indicating strong asset backing.
  • Cash reserves of 84.97M provide robust 1.91x coverage of current liabilities 44.50M, indicating strong short-term solvency.
  • Strong cash position of 84.97M provides 3.36x coverage of other current liabilities 25.31M, indicating excellent liquidity.

Cons

  • Investment activities of (150000) provide weak support for R&D spending of 46.17M, which is -0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (80.29M) shows concerning coverage of stock compensation expenses of 12.14M, with a -6.62 ratio indicating potential earnings quality issues.
  • Free cash flow of (80.44M) provides weak coverage of capital expenditures of 150000, with a -536.27 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (59.86M) show weak coverage of depreciation charges of 3.19M, with a -18.78 ratio indicating high capital intensity and potential reinvestment needs.
  • High financing cash flow of 58.53M relative to working capital of 65.27M, which is 0.90x suggests concerning dependence on external funding for operational needs.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 1.89 12.31
EV to Cash from Ops. -3.28 23.25
EV to Debt 98.45 738.44
EV to EBIT -4.40 -9.16
EV to EBITDA -4.46 6.95
EV to Free Cash Flow [EV/FCF] -3.28 21.90
EV to Market Cap 0.89 65.67
EV to Revenue 5.27 227.32
Price to Book Value [P/B] 3.17 22.34
Price to Earnings [P/E] -4.94 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.00 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % -3.45 -27.13
Cash and Equivalents Growth (1y) % -20.49 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % 73.41 -46.93
EBITDA Growth (1y) % 74.58 -1.68
EBIT Growth (1y) % 73.41 -56.45
EBT Growth (1y) % 73.41 -12.70
EPS Growth (1y) % 76.02 -28.31
FCF Growth (1y) % 58.16 -31.90
Gross Profit Growth (1y) % 337.75 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.36 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 1.91 3.85
Current Ratio 2.47 7.27
Debt to Equity Ratio 0.03 0.40
Interest Cover Ratio 0.00 841.00
Times Interest Earned 0.00 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % -113.30 -18,234.31
EBIT Margin % -119.63 -18,580.80
EBT Margin % -119.63 -19,488.74
Gross Margin % 93.30 -7.59
Net Profit Margin % -119.60 -19,439.22